Vertex Pharmaceuticals (NASDAQ ... tests as it seeks to expand beyond its core franchise. With several key pipeline readouts on the horizon and new product launches underway, Vertex finds itself ...

Vertex Pharmaceuticals (NASDAQ:VRTX) continues to dominate the cystic fibrosis (CF) treatment market, but the biotechnology company faces crucial tests as it seeks to expand beyond its core franchise.

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Buy ...

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity was originally published by The Motley Fool ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid ...

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...